Treatment recommendations for radioimmunotherapy in follicular lymphoma: A consensus conference report

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1188-1199

  Witzig, Thomas E ^a   Fishkin, Paul ^b   Gordon, Leo I ^c   Gregory, Stephanie A ^d   Jacobs, Samuel ^e   MacKlis, Roger ^f   McLaughlin, Peter ^g   Press, Oliver ^h   Zelenetz, Andrew D ⁱ  

^a MAYO CLINIC   (United States)

^b Illinois Cancer Care   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

131I tositumomab; 90Y ibritumomab tiuxetan; Follicular lymphoma; non Hodgkin lymphoma; radioimmunotherapy; treatment algorithm

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

B LYMPHOCYTE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FOLLICULAR LYMPHOMA; HUMAN; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT RESPONSE;

ALGORITHMS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, FOLLICULAR; RADIOIMMUNOTHERAPY; RECURRENCE; TREATMENT OUTCOME;

EID: 79959576404     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.570396     Document Type: Review

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO. Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park) 2005;19:213-228. (Pubitemid 350054581)
3. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23: 8447-8452.
4. Zevalin (90-Y ibritumomab tiuxetan) US prescribing information. 2009. Available from:
5. Bexxar (tositumomab and iodine I 131 tositumomab) US prescribing information. 2005. Available from:
6. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465-474. (Pubitemid 39586026)
7. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti- B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39:21S-27S. (Pubitemid 28371372)
8. NCCN Clinical Practice Guidelines in Oncology: Non- Hodgkin's Lymphomas v.1.2010. 2010. Available from:
9. Illidge TM. Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? J Clin Oncol 2010;28:2944-2946.
10. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576-4582. (Pubitemid 40807274)
11. Vose JM, Bierman PJ, Loberiza FR Jr, Bociek RG, Matso D, Armitage JO. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007;48:683-690. (Pubitemid 46605539)
12. Zevalin (90-Y ibritumomab tiuxetan) EMEA prescribing information. 2008. Available from: . eu/humandocs/PDFs/EPAR/zevalin/H-547-PI-en.pdf
13. Gregory S, Leonard J, Vose J, et al. Superior outcomes associated with earlier use: experience with tositumomab and iodine I 131 tositumomab in 1,177 patients with low-grade, follicular, and transformed non-Hodgkin's lymphoma. J Clin Oncol 2005;23(16 Suppl.): Abstract 6561.
14. Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:629-636.
15. Palanca-Wessels MC, Press OW. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 2010;116:1126-1133.
16. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696-5704.
17. Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010;28:3035-3041.
18. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I- 131 tositumomab for previously untreated follicular non- Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24: 4143-4149. (Pubitemid 46622291)
19. Jacobs SA, Swerdlow SH, Kant J, et al. Phase II trial of shortcourse CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:7088-7094.
20. Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009;9:223-228.
21. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-449. (Pubitemid 40175970)
22. Kaminski M, Tuck M, Estes J, et al. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage follicular lymphoma: median 10 year follow-up results. Blood 2009;114(Suppl. 1): Abstract 3759.
23. Roboz GJ, Bennett JM, Coleman M, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res 2007;31:1141-1144.
24. Link B, Kaminiski M, Coleman M, Leonard J. Phase II study of CVP followed by tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol 2004;22(14 Suppl.): Abstract 6520.
25. Mehta DR, Jankowitz RC, Lenzner DE, Land SR, Jacobs SA. Phase II study of short course CHOP-rituximab followed by 90Y-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: extended follow-up and predictors of relapse. J Clin Oncol 2010;28(15 Suppl.): Abstract 8066.
26. McLaughlin P, Neelapu S, Fanale M, et al. R-FND followed by radioimmunotherapy for high-risk follicular lymphoma. Blood 2008;112(Suppl. 1): Abstract 3056.
27. Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008;9:352-358.
28. Zinzani P, Tani M, Broccoli A, et al. A phase II trial of R-FM (rituximab, fludarabine and mitoxantrone) chemotherapy followed by yttrium-90 ibritumomab tiuxetan (90Y-IT) for untreated follicular lymphoma (FL) patients. Blood 2009;114(Suppl. 1): Abstract 3743.
29. Morschhauser F, Radford J, Van HA, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.
30. Goff L, Summers K, Iqbal S, et al. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol 2009;27: 6094-6100.
31. Morschhauser F, Bischof-Delaloye A, Rohatiner A, et al. Extended follow-up of the international randomized phase 3 First-Line Indolent Trial (FIT) shows durable benefit of 90Yibritumomab tiuxetan (Zevalin1) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma. Blood 2008;112(Suppl. 1): Abstract 2002.
32. Fisher RI. Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma. S0016. A phase III trial of CHOP vs CHOP+rituximab vs CHOP+iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. Clin Adv Hematol Oncol 2005;3:544-546.
33. Bachy E, Brice P, Delarue R, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2010;28:822-829.
34. Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol 2010;28(15 Suppl.): Abstract 8004.
35. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23:712-719. (Pubitemid 46224170)
36. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory lowgrade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928. (Pubitemid 32912019)
37. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-3803.
38. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-2463. (Pubitemid 34525730)
39. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336-4342. (Pubitemid 34627198)
40. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-3269. (Pubitemid 34831524)
41. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004;103:4429-4431. (Pubitemid 38745967)
42. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565-7573. (Pubitemid 46291820)
43. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109:1804-1810. (Pubitemid 46668544)
44. Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I- 131 tositumomab for non-Hodgkin lymphoma. Cancer 2006;106:616-622. (Pubitemid 43157625)
45. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3885-3890.
46. Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to yttrium90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma 2004;5:202-204. (Pubitemid 40227714)
47. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005;23:7985-7993. (Pubitemid 46657399)
48. WisemanG,Geyer S, Porrata L, et al.Ongoing results of a phase I trial of two sequential doses of Y-90 ibritumomab tiuxetan (Zevalin1) for patients with relapsed low-grade non-Hodgkin lymphoma (NHL). AnnOncol 2005;16(Suppl. 2): Abstract 333.
49. Czuczman M, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in lowgrade or follicular lymphoma. J Clin Oncol 2005;23:694-704. (Pubitemid 46224168)
50. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906. (Pubitemid 46613489)